Literature DB >> 25576960

Leiomyosarcoma of the mesentry, a rare mesentric tumour.

Abbas K Sidhic1, Mannalakkal Ranjith1, Karat Parambil Abid Ali2, Pappala Rahul Tej1.   

Abstract

Leiomyosarcoma is extremely rare with a reported incidence of 1:350,000. So accurate preoperative diagnosis of mesenteric soft tissue tumor is generally difficult. Leiomyosarcoma is a malignant tumour arising from smoothcell lineage. Mesenteric leiomyosarcoma occurs most commonly in middle-aged individuals. We describe a case of leiomyosarcoma arising from the ileal mesentery in a 33 year old male patient. The diagnosis was based on histopathologic evaluation using immunohistochemical staining.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Gastrointestinal stromal tumour; Keywords; Leiomyosacoma; Mesenchymal tumour

Year:  2014        PMID: 25576960      PMCID: PMC4336420          DOI: 10.1016/j.ijscr.2014.11.082

Source DB:  PubMed          Journal:  Int J Surg Case Rep        ISSN: 2210-2612


Introduction

Leiomyosarcoma is a malignant mesenchymal tumor that derives from the smooth muscle lineage [1]. The underlying genetic mechanisms remain unclear and complex. Unbalanced karyotypic defects are the only shared features observed across the different leiomyosarcoma subtypes. Cell-cycle perturbations, mainly through RB1 defects, and phosphatidylinositol 3 kinase/Akt pathway activation caused by PTEN genomic deletion are the two most consistent drivers commonly observed in sarcomas, including leiomyosarcoma [1]. Mesenteric leiomyosarcoma likely derives from the smooth muscle of blood vessels in the mesentery [3], and little information is available regarding clinical presentation, pathology, treatment and prognosis. The occurrence of primary mesenteric leiomyosarcoma is extremely rare and very few cases appear to have been reported. So accurate preoperative diagnosis of mesenteric tumor is generally difficult.

Presentation of case

A 33 year old male patient presented with diffuse abdominal pain and difficulty in passing stools for the past 3 years . Pain was diffuse dull aching in character, mainly aggravated during night and relieved on lying in prone position. Later pain shifted to left side of abdomen. He complains of passing mucous in stools. He has loss of appetite and early satiety with occasional episodes of nausea for the past 6 months. No history of malena, fever, vomiting, loss of weight . He was treated as a case of irritable bowel syndrome for past 3 years. On examination, a well defined firm tender mass of 10 × 10 cms was felt in the left lumbar and umbilical region. It was freely mobile in the direction perpendicular to mesentery, with nodular surface. No movement with respiration and on percussion an impaired resonant note was heard. Per rectal examination was with in normal limits. Based on the clinical findings a provisional diagnosis of mesenteric mass was made and further investigated. USG abdomen showed lobulated hypoechoic intra abdominal mass lesion. GIST, with areas of vascularity. CECT abdomen revealed large neoplasm 8.6 × 9.7 × 9.0 cms in abdomen related to mesentry displacing the adjacent intestine. No invasion to adjacent organs. No metastasis to liver. No enlarged lymph nodes. Intra operatively there was a large lobulated 15 × 15 cm tumor in the small bowel mesentry at the transition zone of jejunum and ileum without any breach the peritoneal covering. There is no mesenteric lymphadenopathy, no infiltration to bowel, no ascites and no liver/pelvic/peritoneal metastasis. So resection of tumour with a segment of small bowel was done (Fig. 1 and 2). Histopathology came as leiomyosarcoma, FNCLCC grade 3, involving mesentery, resected small bowel are unremarkable (Fig. 3 and 4). Immunohistochemistry was strongly positive for SMA and CD99 and negative for CD117, CD 34, abd bcl-2 [2]. The mitotic rate was 8/10HPF with atypical mitosis.

Discussion

Primary mesenteric leiomyosarcoma in adolescent patients is exceedingly rare, with little known about its pathology. Mesenteric leiomyosarcoma in an adult was first described by Yannopoulos and Stout et al. [3]. The differential diagnosis includes leiomyosarcoma and other mesenteric tumors such as GIST, malignant myofibroblastic tumor, solitary fibroustumor, liposarcoma, and lymphoma [2]. Generally, percutaneous biopsy is contraindicated because skin metastasis and peritoneal dissemination may be induced by biopsy. A definitive diagnosis of leiomyosarcoma can only be made by histopathologic study, including immunohistochemical staining and genetic analysis. Treatment strategies for mesenteric leiomyosarcoma vary. Surgical excision with a wide margin of normal tissue is most effective since adjuvant chemotherapy or radiotherapy are unreliable [4]. In our case enblock resection was done and the margins were free from tumor. Lee noted that surgeons should attempt to improve the survival rate by radical removal of all smooth muscle tumors, including the removal of at least 4 inches of healthy tissue on all sides of the tumor, plus the corresponding mesentery [6]. Patients with leiomyosarcoma of the bowel mesentery generally display a poor prognosis. The overall 5-year survival rate for this tumor is only 20%–30% [5], and complete primary surgical resection is critical for achieving the best outcome. Conversely, recurrence can occur within 5 years, so that close and long term follow-up of such patients for 5 years or more, with particular attention to the gastrointestinal tract, liver, and lung, is necessary. Pathologically, leiomyosarcoma exhibits high mitotic activity. Survival is influenced by the histological grade of mesenteric leiomyosarcomas, based on cell differentiation, cellularity of the tumor, anaplasia, and number of mitoses per HPF. Ranchod and Kempson showed frequency of mitoses to be the most useful indicator of malignant potential [7]. Simpson et al. introduced histological grading of intestinal leiomyosarcomas [8]. Grade 3 has marked cellularity anaplasia, and a mitotic index more than 10 mitoses per 10HPFs. As our histopathology showed FNCLCC grade 3 and mitotic rate of 8/10HPF, patient was put on radiotherapy for further management. Guidelines for the management of gastrointestinal leiomyosarcoma or mesenteric leiomyosarcoma are unclear, probably because of the small number of patients reported. Earlier detection using ultrasonography and computed tomography, as well as complete surgical resection, may improve long-term prognosis in patients with primary leiomyosarcoma of mesenteric origin.

Conclusion

Primary mesenteric leiomyosarcoma is a rare entity. Because of its rarity there is no uniform treatment modality for the same. Diagnosis can only be confirmed by histopathology and immunological staining. Even though surgery is the main modality of treatment recurrence is common with this. Early detection and wide surgical resection will improve the prognosis of this type of lesion.

Conflict of interest

No conflict of interest.

Funding

No source of funding or no sponsors.

Ethical approval

As this is a case report got the approval from an institutional ethical commitee.

Authors contribution

Concent

As this is a case report got the informed consent from the patient.
Contributor 1Contributor 2Contributor 3Contributor 4
Concepts
Design
Definition of intellectual content
Literature search
Clinical studies
Experimental studies
Data acquisition
Data analysis
Statistical analysis
Manuscript preparation
Manuscript editing
Manuscript review
Guarantor
  7 in total

1.  PRIMARY SOLID TUMORS OF THE MESENTERY.

Authors:  K YANNOPOULOS; A P STOUT
Journal:  Cancer       Date:  1963-07       Impact factor: 6.860

2.  An unusual abdominal tumor--leiomyosarcoma of the mesentery: a case report.

Authors:  Catherine J Simonovich; John M Hardman; James J Navin; Jennifer Jacobs; Neil Fergusson
Journal:  Hawaii Med J       Date:  2006-01

Review 3.  Infantile intestinal leiomyosarcoma: surgical resection (without adjuvant therapy) for cure.

Authors:  B B Simpson; E M Reynolds; S H Kim; W S Ferguson; F Graeme-Cook; D P Doody
Journal:  J Pediatr Surg       Date:  1996-11       Impact factor: 2.545

Review 4.  Leiomyosarcoma.

Authors:  César Serrano; Suzanne George
Journal:  Hematol Oncol Clin North Am       Date:  2013-08-26       Impact factor: 3.722

5.  Malignant smooth muscle tumors of the retroperitoneum and mesentery: a clinicopathologic analysis of 44 cases.

Authors:  H Hashimoto; M Tsuneyoshi; M Enjoji
Journal:  J Surg Oncol       Date:  1985-03       Impact factor: 3.454

6.  Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases.

Authors:  M Ranchod; R L Kempson
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

Review 7.  Leiomyosarcoma of the gastro-intestinal tract: general pattern of metastasis and recurrence.

Authors:  Y T Lee
Journal:  Cancer Treat Rev       Date:  1983-06       Impact factor: 12.111

  7 in total
  5 in total

1.  Ileal Mesenteric Leiomyosarcoma--Report of a Rare Neoplasm.

Authors:  Senjuti Dasgupta; Sudipta Chakrabarti; Suman Ghosh; Shikha Das
Journal:  J Gastrointest Cancer       Date:  2016-03

2.  Curative resection for leiomyosarcoma of the descending mesocolon with metachronous liver metastasis: A case report and literature review.

Authors:  Takaharu Kato; Hiroshi Noda; Iku Abe; Sergio Alonso; Nobu Yokoyama; Toshiki Rikiyama
Journal:  Mol Clin Oncol       Date:  2016-04-25

3.  Primary Leiomyosarcoma of the Mesentery: A Case Report.

Authors:  Varsha Dalal; Manveen Kaur; Reetika Menia; Fouzia Siraj; Amar Bhatnagar; Usha Agrawal
Journal:  Iran J Med Sci       Date:  2017-09

4.  A mesenteric solid tumor with unusual features in a young male: A case report.

Authors:  Yoshitoshi Ichikawa; Tamaki Maeda; Gaku Mizojiri; Satoshi Ishikawa; Takaomi Hagi; Kimiaki Hattori; Hiroshi Oka
Journal:  Mol Clin Oncol       Date:  2017-07-25

5.  DOG1-Positive Primary Mesenteric Leiomyosarcoma: Report of a Case and Review of the Literature.

Authors:  Nektarios Koufopoulos; Vasileia Damaskou; Vasiliki Siozopoulou; Panagiotis Kokoropoulos; Alina-Roxani Gouloumis; Nikolaos Arkadopoulos; Ioannis G Panayiotides
Journal:  Cureus       Date:  2022-05-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.